Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics: Director Alethia Young resigns from board, stays on as consultant

Neutral Impact 2 of 5 leadership Written later

PTC Therapeutics director Alethia Young resigned from the board effective June 8, 2026, citing commitments to other work activities and not any disagreement with the company. She will remain as an advisor under a consulting agreement running through June 8, 2027, for a monthly fee of $4,166.67.

Key points

  • Alethia Young resigned from the board of directors effective June 8, 2026.
  • Resignation was stated to be due to her need to focus on other work commitments, not a disagreement with the company.
  • Consulting agreement runs June 8, 2026 through June 8, 2027, at $4,166.67 per month (Exhibit 10.1).

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECJun 9, 2026, 5:15 PM ET
Accession number0001104659-26-071916

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.